Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity

mBio

Volumn 1, Issue 4, 2010, Pages

  Cervantes Barragan, Luisa ^a,b   Züst, Roland ^a   Maier, Reinhard ^a   Sierro, Sophie ^c   Janda, Jozef ^c   Levy, Frederic ^c   Speiser, Daniel ^c   Romero, Pedro ^c   Rohrlich, Pierre Simon ^d,e,f   Ludewig, Burkhard ^a,g   Thiel, Volker ^a,g  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d INSERM   (France)

^e UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; CORONA VIRUS VACCINE; DENDRITIC CELL VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CORONAVIRUS; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; UPREGULATION; VACCINATION; VIRUS IMMUNITY; VIRUS REPLICATION;

CORONAVIRUS; HUMAN CORONAVIRUS 229E; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINE HEPATITIS VIRUS;

EID: 79952143410     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00171-10     Document Type: Article

References (55)

1. McMichael, A. J. 2006. HIV vaccines. Annu. Rev. Immunol. 24:227-255.
2. Strickland, G. T., S. S. El Kamary, P. Klenerman, and A. Nicosia. 2008. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis. 8:379-386.
3. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29:372-383.
4. Appay, V., D. C. Douek, and D. A. Price. 2008. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14:623-628.
5. Tacken, P. J., I. J. de Vries, R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7:790-802.
6. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449:419-426.
7. Ludewig, B., S. Ehl, U. Karrer, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1998. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 72:3812-3818.
8. Ludewig, B., K. J. Maloy, C. Lopez-Macias, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 2000. Induction of optimal anti-viral neutralizing B cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. Eur. J. Immunol. 30:185-196.
9. Ludewig, B., S. Oehen, F. Barchiesi, R. A. Schwendener, H. Hengartner, and R. M. Zinkernagel. 1999. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol. 163:1839-1844.
10. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191:795-804.
11. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213-1221.
12. Rea, D., M. J. Havenga, M. van Den Assem, R. P. Sutmuller, A. Lemckert, R. C. Hoeben, A. Bout, C. J. Melief, and R. Offringa. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166:5236-5244.
13. Palucka, A. K., H. Ueno, J. W. Fay, and J. Banchereau. 2007. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220:129-150.
14. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815-824.
15. Tacken, P. J., I. J. de Vries, K. Gijzen, B. Joosten, D. Wu, R. P. Rother, S. J. Faas, C. J. Punt, R. Torensma, G. J. Adema, and C. G. Figdor. 2005. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106:1278-1285.
16. Meyer-Wentrup, F., D. Benitez-Ribas, P. J. Tacken, C. J. Punt, C. G. Figdor, I. J. de Vries, and G. J. Adema. 2008. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111:4245-4253.
17. Steinman, R. M. 2008. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29:319-324.
18. Rea, D., M. E. Johnson, M. J. Havenga, C. J. Melief, and R. Offringa. 2001. Strategies for improved antigen delivery into dendritic cells. Trends Mol. Med. 7:91-94.
19. Cheng, C., J. G. Gall, W. P. Kong, R. L. Sheets, P. L. Gomez, C. R. King, and G. J. Nabel. 2007. Mechanism of aD5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3:e25.
20. Ageichik, A., M. K. Collins, and M. Dewannieux. 2008. Lentivector targeting to dendritic cells. Mol. Ther. 16:1008-1009.
21. Flatz, L., A. N. Hegazy, A. Bergthaler, A. Verschoor, C. Claus, M. Fernandez, L. Gattinoni, S. Johnson, F. Kreppel, S. Kochanek, M. Broek, A. Radbruch, F. Levy, P. H. Lambert, C. A. Siegrist, N. P. Restifo, M. Lohning, A. F. Ochsenbein, G. J. Nabel, and D. D. Pinschewer. 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16:339-345.
22. Nishimoto, K. P., A. K. Laust, K. Wang, K. I. Kamrud, B. Hubby, J. F. Smith, and E. L. Nelson. 2007. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 20:88-104.
23. Polo, J. M., J. P. Gardner, Y. Ji, B. A. Belli, D. A. Driver, S. Sherrill, S. Perri, M. A. Liu, and T. W. Dubensky, Jr. 2000. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) 104:181-185.
24. Krebs, P., E. Scandella, B. Odermatt, and B. Ludewig. 2005. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J. Immunol. 174:4559-4566.
25. Yang, T. C., J. Millar, T. Groves, N. Grinshtein, R. Parsons, S. Takenaka, Y. Wan, and J. L. Bramson. 2006. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J. Immunol. 176:200-210.
26. Lopes, L., M. Dewannieux, U. Gileadi, R. Bailey, Y. Ikeda, C. Whittaker, M. P. Collin, V. Cerundolo, M. Tomihari, K. Ariizumi, and M. K. Collins. 2008. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 82:86-95.
27. Dobbelstein, M. 2003. Viruses in therapy-royal road or dead end? Virus Res. 92:219-221.
28. Züst, R., L. Cervantes-Barragan, T. Kuri, G. Blakqori, F. Weber, B. Ludewig, and V. Thiel. 2007. Identification of coronavirus non-structural protein 1 as a major pathogenicity factor-implications for the rational design of live attenuated coronavirus vaccines. PLoS Pathog. 3:e109.
29. de Haan, C. A., P. S. Masters, X. Shen, S. Weiss, and P. J. Rottier. 2002. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296:177-189.
30. Thiel, V., N. Karl, B. Schelle, P. Disterer, I. Klagge, and S. G. Siddell. 2003. Multigene RNA vector based on coronavirus transcription. J. Virol. 77:9790-9798.
31. Summers, K. L., B. D. Hock, J. L. McKenzie, and D. N. Hart. 2001. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am. J. Pathol. 159:285-295.
32. Zhou, H., and S. Perlman. 2006. Preferential infection of mature dendritic cells by mouse hepatitis virus strain JHM. J. Virol. 80:2506-2514.
33. Ortego, J., D. Escors, H. Laude, and L. Enjuanes. 2002. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J. Virol. 76:11518-11529.
34. Oehen, S., T. Junt, C. Lopez-Macias, and T. A. Kramps. 2000. Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA. Immunology 99:163-169.
35. Valmori, D., F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J. C. Cerottini, and P. Romero. 2000. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164:1125-1131.
36. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711.
37. Kuo, L., and P. S. Masters. 2003. The small envelope protein E is not essential for murine coronavirus replication. J. Virol. 77:4597-4608.
38. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78:5535-5545.
39. Pircher, H., D. Moskophidis, U. Rohrer, K. Burki, H. Hengartner, and R. M. Zinkernagel. 1990. Viral escape by selection of cytotoxic T cellresistant virus variants in vivo. Nature 346:629-633.
40. Hudrisier, D., M. B. Oldstone, and J. E. Gairin. 1997. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules. Virology 234:62-73.
41. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161:2187-2194.
42. Pajot, A., M. L. Michel, N. Fazilleau, V. Pancre, C. Auriault, D. M. Ojcius, F. A. Lemonnier, and Y. C. Lone. 2004. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 34:3060-3069.
43. Yeager, C. L., R. A. Ashmun, R. K. Williams, C. B. Cardellichio, L. H. Shapiro, A. T. Look, and K. V. Holmes. 1992. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357:420-422.
44. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U. S. A. 91:6196-6200.
45. Trono, D. 2003. Virology. Picking the right spot. Science 300:1670-1671.
46. Crotty, S., B. L. Lohman, F. X. Lu, S. Tang, C. J. Miller, and R. Andino. 1999. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J. Virol. 73:9485-9495.
47. Harvey, T. J., I. Anraku, R. Linedale, D. Harrich, J. Mackenzie, A. Suhrbier, and A. A. Khromykh. 2003. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J. Virol. 77:7796-7803.
48. Hickman, H. D., K. Takeda, C. N. Skon, F. R. Murray, S. E. Hensley, J. Loomis, G. N. Barber, J. R. Bennink, and J. W. Yewdell. 2008. Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat. Immunol. 9:155-165.
49. Junt, T., E. A. Moseman, M. Iannacone, S. Massberg, P. A. Lang, M. Boes, K. Fink, S. E. Henrickson, D. M. Shayakhmetov, N. C. Di Paolo, N. van Rooijen, T. R. Mempel, S. P. Whelan, and U. H. von Andrian. 2007. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450:110-114.
50. Cervantes-Barragan, L., U. Kalinke, R. Zust, M. Konig, B. Reizis, C. Lopez-Macias, V. Thiel, and B. Ludewig. 2009. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J. Immunol. 182:1099-1106.
51. Harty, J. T., and V. P. Badovinac. 2008. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 8:107-119.
52. Draper, S. J., A. C. Moore, A. L. Goodman, C. A. Long, A. A. Holder, S. C. Gilbert, F. Hill, and A. V. Hill. 2008. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14:819-821.
53. Yang, L., H. Yang, K. Rideout, T. Cho, K. I. Joo, L. Ziegler, A. Elliot, A. Walls, D. Yu, D. Baltimore, and P. Wang. 2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26:326-334.
54. Eriksson, K. K., D. Makia, and V. Thiel. 2008. Generation of recombinant coronaviruses using vaccinia virus as the cloning vector and stable cell lines containing coronaviral replicon RNAs. Methods Mol. Biol. 454:237-254.
55. Waeckerle-Men, Y., E. U. Allmen, R. von Moos, B. J. Classon, E. Scandella, H. P. Schmid, B. Ludewig, M. Groettrup, and S. Gillessen. 2005. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 64:323-331.